论文部分内容阅读
目的 :探讨联合检测肿瘤标记物CA1 2 5 、CA1 9- 9、SF、β2 -MG在卵巢恶性肿瘤的诊断和预后的临床意义。方法 :应用放射免疫测定法测定了 61例卵巢良性肿瘤及 40例卵巢恶性肿瘤患者术前术后血清中肿瘤标记物进行比较。结果 :上述肿瘤标记物单项检测卵巢恶性肿瘤阳性率为 3 6.1%～ 85 % ,以CA1 2 5 最高 ,而以其中任意三项或三项以上组合检测阳性率为 72 .5 %～ 95 % ,且CA1 2 5 、CA1 9- 9、SF三项与上述四项组合组阳性率相同达 95 % ,即使Ⅰ期病例也可达 89.4% ,对Ⅲ、Ⅳ期及复发病例阳性率可达 10 0 %。结论 :肿瘤标记物联合检测对早期发现复发有一定意义。
Objective: To investigate the clinical significance of the combined detection of tumor markers CA1 2 5, CA1 9-9, SF, β2-MG in the diagnosis and prognosis of ovarian cancer. Methods: Tumor markers in 61 cases of benign ovarian tumors and 40 cases of ovarian malignant tumors were measured by radioimmunoassay before and after surgery. Results: The positive rate of malignant ovarian tumors detected by single tumor markers was 31.6% ~ 85%, the highest was CA1 2 5, while the positive rate was 72.5% ~ 95% with any three or more of them, The positive rates of CA1 2 5, CA1 9-9 and SF were the same as those of the above four combinations, reaching 95% even in stage Ⅰ, and the positive rates of stage Ⅲ, stage Ⅳ and recurrence were 10 0 %. Conclusion: The combined detection of tumor markers has some significance for early detection of recurrence.